



ASX RELEASE
26 February 2013

Tissue Therapies Limited (ASX: TIS) - Underwritten rights issue

Tissue announces that it has an underwriting commitment in respect of the A\$4.5 million rights issue.

Tissue is pleased to confirm that, subject to the usual terms and conditions, Bell Potter Securities Limited and RBS Morgans Corporate Limited have agreed to fully underwrite its A\$4.5 million 1-for-10 non-renounceable rights issue.

Managing Director, Dr Steven Mercer stated "Tissue appreciates the ongoing support of the Joint Lead Managers to its A\$13.2 million capital raising, comprising the A\$8.7 million placement announced on 25 February 2013 and the follow-on rights issue. The rights issue will provide an opportunity for eligible existing shareholders to participate at the same price as sophisticated and institutional investors under the placement. The underwritten offer will allow the company to proceed with confidence and move quickly to focus upon its immediate commercial objectives."

Tissue Therapies Limited ABN 45 101 955 088 www.tissuetherapies.com
Level 19, 179 Turbot Street, Brisbane QLD 4000 Australia
GPO Box 1596, Brisbane QLD 4001
telephone +61 7 3334 3900 facsimile +61 7 3334 3999

What is VitroGro® ECM

- VitroGro® ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro® ECM replaces the degraded matrix of a hard to heal wound. VitroGro® ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration ^[1].
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process ^[1,2,3,4]. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds ^[1]. VitroGro® ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modeling indicates that VitroGro® ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: www.tissuetherapies.com

Tissue Therapies Limited ABN 45 101 955 088 www.tissuetherapies.com

Level 19, 179 Turbot Street, Brisbane QLD 4000 Australia

GPO Box 1596, Brisbane QLD 4001

telephone +61 7 3334 3900 facsimile +61 7 3334 3999